Clinical Trial

A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease

Study acronym: OMICROHN
Recruiting
View on ClinicalTrials.gov →
Summary
This is a multicentre, prospective, randomised, controlled, open-label study to assess the efficacy, safety, and cost-effectiveness of epigenome-guided treatment selection compared to usual standard-of-care (SOC) treatment selection in patients initiating biologic therapy for the treatment of their active Crohn's Disease (CD).
Protocol Amendment History 1 change
notable Trial sites expanded: 30 -> 39 locations 2026-06-02
Trial Details
NCT Number NCT07363044
Lead Sponsor Alimentiv Inc.
Collaborators: The Leona M. and Harry B. Helmsley Charitable Trust, Horizon Europe, Stichting Amsterdam UMC
Conditions Crohn Disease (CD)
Enrollment 378 participants
Start Date 2025-02-01
Primary Completion 2027-06 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-01